Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Frequently asked questions
What sector does Theravance Biopharma Inc (TBPH) operate in?
Theravance Biopharma Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Theravance Biopharma Inc (TBPH) current stock price?
As of the latest data, Theravance Biopharma Inc stock price is $17.03, with a previous close of $17.03.
What is Theravance Biopharma Inc (TBPH) current market capitalization?
Theravance Biopharma Inc market cap is approximately 884.18 million.
What is Theravance Biopharma Inc (TBPH) Earnings Per Share (EPS)?
The trailing EPS is $1.04, and the forward EPS is $1.28.
What is Theravance Biopharma Inc (TBPH) Price-to-Earnings (P/E) ratio?
Theravance Biopharma Inc current P/E ratio is 16.38, with a forward P/E of 13.36.
What is Theravance Biopharma Inc (TBPH) EBITDA?
Theravance Biopharma Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 839.00 thousand.
Does Theravance Biopharma Inc (TBPH) pay dividends?
No. Theravance Biopharma Inc does not pay a dividend.
How did Theravance Biopharma Inc (TBPH) perform in its most recent earnings report?
In the last report (June 30, 2026), Theravance Biopharma Inc posted an EPS surprise of -50% and a revenue surprise of -7.14%.
What is Theravance Biopharma Inc (TBPH) beta (volatility) score?
Theravance Biopharma Inc has a beta of 0.245, indicating lower volatility than the overall market.
